

Lesotho Support for Pneumococcal Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Lesotho								
2. Grant number: 1922-LSO-12d-X, 12-LSO-08a-Y/18-LSO-25a-Y								
3. Date of Decision Letter: 12 March 2019								
4. Date of the Partnership Framework Agreement: 30 November 2012								
5. Programme title: New Vaccine Support (NVS), Pneumococcal Routine								
6. Vaccine type: Pneumococcal								
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 4 dose(s) per vial , LIQUID								
8. Programme duration¹: 2012 -2022								
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)								
	2012-2018	2019	2020	2021	2022	Total ²		
Programme Budget (US\$)	US\$1,864,568 ³	US\$266,500	US\$330,500	US\$329,000	US\$324,500	US\$3,115,068		
10. Vaccine introduction grant (in US\$) US\$ 100,000 was disbursed on 1 October 2014								
11. Product Switch Grant (in US\$)								
<table border="1" style="margin: auto;"> <tr> <td style="padding: 5px;">2018</td> </tr> <tr> <td style="padding: 5px;">25,877</td> </tr> </table>							2018	25,877
2018								
25,877								
12. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴								
Type of supplies to be purchased with Gavi funds in each year	2012-2018		2019					
Number of Pneumococcal vaccines doses			78,800					
Annual Amounts (US\$)	US\$1,864,568 ⁵		US\$266,500					

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

13. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.				
14. Self-procurement: Not applicable				
15. Co-financing obligations: Reference code: 1922-LSO-12d-X-C According to the co-financing policy, the Country falls within the group Preparatory transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.				
Type of supplies to be purchased with Country funds in each year	2019	2020	2021	2022
Number of vaccine doses	8,000	12,800	15,000	17,400
Number of AD syringes	7,400	12,800	14,800	17,200
Number of safety boxes	100	150	175	200
Value of vaccine doses (US\$)	US\$23,093	US\$37,731	US\$43,962	US\$50,889
Total co-financing payments (US\$) (including freight)	US\$24,000	US\$39,000	US\$45,500	US\$52,500
16. Additional reporting requirements:				
Reports and other information			Due dates	
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.			May	
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.			To be agreed with Secretariat	
17. Financial clarifications: Not applicable				
18. Other conditions: The country is reminded of its obligations under the PFA in respect of insurance and is requested to provide information to Gavi on the steps it has taken in this regard.				

Signed by,



On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

12 March 2019